Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / MRTX - Mirati Therapeutics submits IND application for MRTX1719 to treat MTAP-deleted cancers

MRTX - Mirati Therapeutics submits IND application for MRTX1719 to treat MTAP-deleted cancers

Mirati Therapeutics Inc.
Mirati Therapeutics (NASDAQ:MRTX) has submitted an Investigational New Drug (IND) application to the FDA to evaluate its synthetic lethal PRMT5 inhibitor, MRTX1719, for the treatment of methylthioadenosine phosphoylase (MTAP)-deleted cancers. The Phase 1/2 clinical development strategy for MRTX1719 is designed to establish a Phase 2 dose and assess the safety, pharmacokinetics and initial clinical activity of MRTX1719 in patients with MTAP-deleted cancers. The Company expects to initiate a Phase 1/2 clinical trial in Q1 2022, pending IND clearance from the FDA.

For further details see:

Mirati Therapeutics submits IND application for MRTX1719 to treat MTAP-deleted cancers
Stock Information
Company Name: Mirati Therapeutics Inc.
Stock Symbol: MRTX
Market: NASDAQ
Website: mirati.com
Menu
MRTX MRTX Quote MRTX Short MRTX News MRTX Articles MRTX Message Board
Get MRTX Alerts

News, Short Squeeze, Breakout and More Instantly...